AI drug discovery company Isomorphic Labs completes $5 billion Series C funding round
Original headlineAI 药物研发公司 Isomorphic Labs 完成 50 亿美元 C 轮融资
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Isomorphic Labs, the AI drug discovery company spun out of Alphabet, raised a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with Alphabet reinvesting and new participation from Andreessen Horowitz alongside existing backers Thrive Capital, GV and Temasek. The company will use the capital to expand its IsoDDE drug design engine into new biological areas and build the operational capacity to push candidate drugs into clinical trials, funding both its internal pipeline and partnered programs. Isomorphic said its internal oncology and immunology programs and collaborative projects have produced positive preclinical results. The round marks one of the largest private fundraises in AI-driven biotech and signals continued investor appetite for computational drug discovery despite a cautious broader venture market. Next milestones to watch are the first clinical trial entries for its internal candidates and the pace at which IsoDDE expands into new therapeutic areas.
Muhabbit's AI wrote this summary in its own words from TechFlow's report and translated it from Chinese. It can get details wrong, so check the source.
Named in this story
Isomorphic Labs, Alphabet (GOOGL), Sequoia Capital, Greenoaks, Andreessen Horowitz, GV, Thrive Capital, Temasek
A linked name opens that asset's sentiment page.